Contineum Therapeutics (CTNM) Enterprise Value (2023 - 2025)
Contineum Therapeutics has reported Enterprise Value over the past 3 years, most recently at -$182.4 million for Q3 2025.
- Quarterly results put Enterprise Value at -$182.4 million for Q3 2025, up 14.73% from a year ago — trailing twelve months through Sep 2025 was -$182.4 million (up 14.73% YoY), and the annual figure for FY2024 was -$204.8 million, down 63.56%.
- Enterprise Value for Q3 2025 was -$182.4 million at Contineum Therapeutics, down from -$175.5 million in the prior quarter.
- Over the last five years, Enterprise Value for CTNM hit a ceiling of -$117.9 million in Q1 2024 and a floor of -$218.7 million in Q2 2024.
- Median Enterprise Value over the past 3 years was -$186.6 million (2025), compared with a mean of -$178.6 million.
- Biggest five-year swings in Enterprise Value: tumbled 63.56% in 2024 and later grew 19.74% in 2025.
- Contineum Therapeutics' Enterprise Value stood at -$125.2 million in 2023, then plummeted by 63.56% to -$204.8 million in 2024, then grew by 10.92% to -$182.4 million in 2025.
- The last three reported values for Enterprise Value were -$182.4 million (Q3 2025), -$175.5 million (Q2 2025), and -$190.7 million (Q1 2025) per Business Quant data.